Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-enter-into-drug-discovery-collaboration-for-neurodegenerative-diseases-6
Evotec completes acquisition of Cyprotex PLC
Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-cyprotex-plc-5418
Evotec and Forge Therapeutics form strategic 'superbug' alliance
Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. („Forge“) to advance its novel Gram-negative antibiotic programme targeting „LpxC“ for the treatment of bacterial infections including those caused by drug resistant ’superbugs‘. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-forge-therapeutics-form-strategic-superbug-alliance-8
Evotec and Merck enter into agreements to collaborate on target discovery technologies
Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck’s portfolio of genome editing technologies with Evotec’s versatile screening platforms and disease expertise. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-merck-enter-into-agreements-to-collaborate-on-target-discovery-technologies-5414
Evotec and Oxford create novel Partnership called 'LAB282'
Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university’s research commercialisation company) and Oxford Sciences Innovation, OSI (the world’s largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-oxford-create-novel-partnership-called-lab282-5408
Evotec AG reports results of first nine months of 2016
Evotec AG today reported financial results and corporate updates for the first nine months of 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-nine-months-of-2016-5410
Evotec announces its intent to acquire Cyprotex PLC
Evotec AG today announced that it has made an offer to acquire Cyprotex PLC („Cyprotex“, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-its-intent-to-acquire-cyprotex-plc-5404
Ad hoc: Evotec AG announces its intent to acquire Cyprotex PLC
Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-announces-its-intent-to-acquire-cyprotex-plc-5626
Evotec and UCB sign multi-year CNS pharmacology agreement
Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-cns-pharmacology-agreement-5402
Evotec and Carrick Therapeutics build strategic alliance
Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-carrick-therapeutics-build-strategic-alliance-5398